logo
Plus   Neg
Share
Email

Meredith Slips To Loss In Q3; Results Miss View

Meredith Corp. (MDP) reported that its third-quarter net loss was $284.4 million or $6.65 per share compared to net income of $23.7 million or $0.10 per share in the prior year.

Loss from continuing operations was $289 million in the third quarter of fiscal 2020. The loss was due primarily to non-cash impairments of goodwill and intangible assets of $296 million as well as lease-related assets exited as part of ongoing synergy activities of $88 million.

Earnings from continuing operations before special items were $0.49 compared to $0.52 last year. Analysts polled by Thomson Reuters expected the company to report earnings of $1.10 per share for the quarter. Analysts' estimates typically exclude special items.

Adjusted EBITDA was $152 million, compared to $161 million in the prior year, hurt primarily by COVID-19-related declines in advertising, partially offset by increased political advertising.

Quarterly revenues were $702 million, a decline of 6 percent from the prior year period, due primarily to previously announced magazine portfolio adjustments to improve profitability that reduced advertising and consumer related revenues by a total of $40 million and COVID-19 related advertising cancellations and delays that reduced revenues by $17 million. The changes were partially offset by $10 million of incremental broadcasting political advertising revenues compared to the prior year period. Analysts expected revenues of $720.83 million for the third-quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT